Genome Research,
Journal Year:
2019,
Volume and Issue:
29(3), P. 418 - 427
Published: Feb. 26, 2019
Cell-free
DNA
(cfDNA)
in
human
plasma
is
a
class
of
biomarkers
with
many
current
and
potential
future
diagnostic
applications.
Recent
studies
have
shown
that
cfDNA
molecules
are
not
randomly
fragmented
possess
information
related
to
their
tissues
origin.
Pathologies
causing
death
cells
from
particular
result
perturbations
the
relative
distribution
affected
tissues.
Such
tissue-of-origin
analysis
particularly
useful
development
liquid
biopsies
for
cancer.
It
therefore
value
accurately
determine
contributions
pool
simultaneous
manner.
In
this
work,
we
report
open
chromatin
regions,
show
characteristic
fragmentation
patterns
reflected
by
sequencing
coverage
imbalance
differentially
phased
fragment
end
signals.
The
latter
refers
differences
read
densities
sequences
corresponding
orientation
upstream
downstream
ends
relation
reference
genome.
preferentially
occur
tissue-specific
regions
where
contributed
into
plasma.
Quantitative
analyses
such
signals
allow
measurement
various
toward
pool.
These
findings
were
validated
data
obtained
pregnant
women,
organ
transplantation
recipients,
cancer
patients.
Orientation-aware
has
applications
noninvasive
prenatal
testing,
monitoring,
biopsy.
Nature Communications,
Journal Year:
2018,
Volume and Issue:
9(1)
Published: Nov. 23, 2018
Abstract
Methylation
patterns
of
circulating
cell-free
DNA
(cfDNA)
contain
rich
information
about
recent
cell
death
events
in
the
body.
Here,
we
present
an
approach
for
unbiased
determination
tissue
origins
cfDNA,
using
a
reference
methylation
atlas
25
human
tissues
and
types.
The
method
is
validated
silico
simulations
as
well
vitro
mixes
from
different
sources
at
known
proportions.
We
show
that
plasma
cfDNA
healthy
donors
originates
white
blood
cells
(55%),
erythrocyte
progenitors
(30%),
vascular
endothelial
(10%)
hepatocytes
(1%).
Deconvolution
patients
reveals
contributions
agree
with
clinical
findings
sepsis,
islet
transplantation,
cancer
colon,
lung,
breast
prostate,
unknown
primary.
propose
procedure
which
can
be
easily
adapted
to
study
cellular
contributors
many
settings,
opening
broad
window
into
pathologic
dynamics.
Molecular Cancer,
Journal Year:
2022,
Volume and Issue:
21(1)
Published: March 18, 2022
Over
the
past
decade,
invasive
techniques
for
diagnosing
and
monitoring
cancers
are
slowly
being
replaced
by
non-invasive
methods
such
as
liquid
biopsy.
Liquid
biopsies
have
drastically
revolutionized
field
of
clinical
oncology,
offering
ease
in
tumor
sampling,
continuous
repeated
devising
personalized
therapeutic
regimens,
screening
resistance.
consist
isolating
tumor-derived
entities
like
circulating
cells,
DNA,
extracellular
vesicles,
etc.,
present
body
fluids
patients
with
cancer,
followed
an
analysis
genomic
proteomic
data
contained
within
them.
Methods
isolation
rapidly
evolved
over
few
years
described
review,
thus
providing
greater
details
about
characteristics
progression,
staging,
heterogeneity,
gene
mutations,
clonal
evolution,
etc.
from
cancer
opened
up
newer
avenues
detection
monitoring,
treatment
based
on
precision
medicine,
markers
Though
technology
is
still
evolving,
its
nature
promises
to
open
new
eras
oncology.
The
purpose
this
review
provide
overview
current
methodologies
involved
their
application
detection,
prognosis,
outcomes.
Biomolecular Detection and Quantification,
Journal Year:
2019,
Volume and Issue:
17, P. 100087 - 100087
Published: March 1, 2019
An
increasing
number
of
studies
demonstrate
the
potential
use
cell-free
DNA
(cfDNA)
as
a
surrogate
marker
for
multiple
indications
in
cancer,
including
diagnosis,
prognosis,
and
monitoring.
However,
harnessing
full
cfDNA
requires
(i)
optimization
standardization
preanalytical
steps,
(ii)
refinement
current
analysis
strategies,
and,
perhaps
most
importantly,
(iii)
significant
improvements
our
understanding
its
origin,
physical
properties,
dynamics
circulation.
The
latter
knowledge
is
crucial
interpreting
associations
between
changes
baseline
characteristics
clinical
manifestations
cancer.
In
this
review
we
explore
recent
advancements
highlight
gaps
concerning
each
point
contact
different
stages
cancer
management.
